Untangling the confusion. Alzheimer's management today.
Wheldon
Megg
M
D000544:Alzheimer Disease / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003221:Confusion / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D006801:Humans; D001523:Mental Disorders / Q000209:etiology / Q000517:prevention & control; D009722:Nurse Practitioners; D024802:Nurse's Role; D011595:Psychomotor Agitation / Q000209:etiology / Q000517:prevention & control; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014481:United States
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D016194:Receptors, N-Methyl-D-Aspartate